Gilead closes $247M HIV drug settlement deal

A California federal judge on Friday approved a nearly $247 million plan to settle claims that Gilead wrongfully kept generic HIV competitors from the market.

Gilead will pay the amount to a settlement fund, which represents about 11.9% of the damages plaintiffs were seeking at trial. Purchasers…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks